Sidebar: Biologics In The Spotlight: Novartis’ Canakinumab
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis' entry among the BLAs with a 2009 user fee goal, canakinumab, well illustrates the company's approach to biologics through the six-year-old Novartis Institute for Biomedical Research.